PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety FollowUp Study Of Cardiovascular Events In Subjects Who Participated In Selected Torcetrapib/Atorvastatin Studies
Terminated
- Conditions
- Cardiovascular DiseaseCerebrovascular Disorders
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2008-02-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 26784
- Registration Number
- NCT00452842
- Locations
- 🇺🇸
Pfizer Investigational Site, Clearwater, Florida, United States
Phase 1 Clinical Trial of Varenicline in Chinese Healthy Smoking Volunteers
Phase 1
Completed
- Conditions
- Smoking
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2008-04-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00452894
- Locations
- 🇨🇳
Pfizer Investigational Site, Beijing, China
Study Of AG-013736 (Axitinib) In Patients With Advanced Solid Tumors
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00447005
- Locations
- 🇯🇵
Pfizer Investigational Site, Kashiwa, Chiba, Japan
Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis
Phase 1
Completed
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2007-03-13
- Last Posted Date
- 2011-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT00446784
- Locations
- 🇺🇸
Pfizer Investigational Site, Ducansville, Pennsylvania, United States
Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis
- First Posted Date
- 2007-03-09
- Last Posted Date
- 2011-08-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 550
- Registration Number
- NCT00445770
- Locations
- 🇯🇵
Pfizer Investigational Site, Toyama, Japan
Dalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients
Phase 4
Terminated
- Conditions
- Venous Thromboembolism
- Interventions
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT00445328
- Locations
- 🇮🇳
Pfizer Investigational Site, Kolkata, West Bengal, India
A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT00445315
- Locations
- 🇬🇧
Pfizer Investigational Site, Dundee, United Kingdom
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 520
- Registration Number
- NCT00444795
- Locations
- 🇰🇷
Hwasun Hospital, Chonnam National University, Cheonnam, Korea, Republic of
🇰🇷Soonchunhyang University Bucheon Hospital, Bucheon, Gyeonggi-do, Korea, Republic of
🇰🇷Chosun University Hospital, Gwang Joo, Korea, Republic of
Evaluation of A Novel Methodology in the Assessment of Urethral Function Using [S,S]-Reboxetine in Healthy Volunteers
Not Applicable
Completed
- Conditions
- Healthy
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2011-06-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00444548
- Locations
- 🇩🇰
Pfizer Investigational Site, Hellerup, Denmark
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
Phase 3
Completed
- Conditions
- Overactive Bladder
- Interventions
- First Posted Date
- 2007-03-08
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1712
- Registration Number
- NCT00444925
- Locations
- 🇺🇦
Pfizer Investigational Site, Zaporizhzhia, Ukraine
© Copyright 2025. All Rights Reserved by MedPath